Abstracts tagged "treatment"

Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Yoshiya Tanaka¹, Shintaro Hirata¹, Shunsuke Fukuyo¹, Masao Nawata², Satoshi Kubo², Kunihiro Yamaoka² and Kazuyoshi Saito¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
Abstract Number: 349 • 2012 ACR/ARHP Annual Meeting
Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab
Clifton O. Bingham III¹, Warren C. Rizzo², Micki Klearman³, Azra Hassanali⁴, Ruchi Upmanyu⁵ and Alan J. Kivitz⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Advanced Arthritis Care & Research, Scottsdale, AZ, ³Genentech Inc, South San Francisco, CA, ⁴Genentech Inc, San Francisco, CA, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Tocilizumab (TCZ) is an IL-6–receptor inhibitor for treatment of rheumatoid arthritis (RA) patients (pts). Because TCZ may impact how IL-6 modulates T-cell activation and…
Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Seung Y. Chu¹, Karen Yeter², Roshan Kotha³, Erik Pong¹, Yvonne Miranda¹, Hsing Chen¹, Sung-Hyung Lee¹, Irene Leung¹, John R. Desjarlais¹, William Stohl² and David E. Szymkowski⁴, ¹Xencor, Inc., Monrovia, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Biotherapeutics, Xencor, Inc., Monrovia, CA
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…
Abstract Number: 1286 • 2012 ACR/ARHP Annual Meeting
Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab
Chad Pool¹, Gopi Shankar², Allen Schantz², George Gunn², Rebecca Bolce³, Marjatta Leirisalo-Repo⁴, Jim Wang¹, John A. Goldman⁵, Raphael J. DeHoratius⁶, Roy Fleischmann⁷ and Dennis Decktor⁶, ¹Janssen Services, LLC, Horsham, PA, ²Janssen R&D, LLC, PA, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁵Medical Quarters #293, Atlanta, GA, ⁶Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁷Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: To determine if RA patients (pts) who had an inadequate response to etanercept(ETN) or adalimumab(ADA) and developed antibodies (Abs) to ETN or ADA responded…
Abstract Number: 470 • 2012 ACR/ARHP Annual Meeting
Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study
Thierry Schaeverbeke¹, Philippe Gaudin², Aleth Perdriger³, Christian Roux⁴, Muriel Vray⁵, Stephanie Rouanet⁶, Ghislaine Steinberg⁷ and Fabien Etchepare⁸, ¹Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ²Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ³Rheumatology, Hôpital Sud, Rennes, France, ⁴Rheumatology, Paris Descartes University, Paris, France, ⁵Institut Pasteur, Paris, France, ⁶Medical Department, Roche, Boulogne, France, ⁷Medical department, Roche, Boulogne, France, ⁸G.H. Pitié-Salpêtrière, Paris, France
Background/Purpose: The anti-IL6-R tocilizumab (TCZ), indicated for the treatment of moderate to severe rheumatoid arthritis (RA), has demonstrated its clinical and structural efficacy in phase…
Abstract Number: 327 • 2012 ACR/ARHP Annual Meeting
Tolerogenic Dendritic Cells Ameliorates the Disease Severity of Murine Collagen-Induced Arthritis
Bin Ning¹, Shang-You Yang², Jianlu Wei¹, Weiming Gong¹ and Paul H. Wooley², ¹Orthopaedic Surgery, Shandong University Jinan Central Hospital, Jinan, China, ²Orthopaedic Research Institute, Via Christi Wichita Hospitals, Wichita, KS
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by synovial inflammation, cartilage breakdown and bone destruction with the involvement of various types of…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 1290 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Roy Fleischmann², Jean Davignon³, Howard Schwartz⁴, Scott Turner⁵, Carine Beysen⁵, Mark Milad⁶, Zheng Luo⁷, John Bradley⁸, Irina Kaplan⁸, Richard Riese⁷, Andrea Zuckerman⁷ and Iain B. McInnes⁹, ¹University of California, Los Angeles, CA, ²Metroplex Clinical Research Center, Dallas, TX, ³University of Montreal, Montreal, Canada, ⁴Miami Research Associates, Miami, FL, ⁵KineMed Inc., Emeryville, CA, ⁶Milad Pharmaceutical Consulting LLC, Plymouth, MI, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc, Groton, CT, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…
Abstract Number: 473 • 2012 ACR/ARHP Annual Meeting
The Addition of Another Disease-Modifying Anti-Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During 2 Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis
Hideto Kameda¹, Takahiko Kurasawa¹, Hayato Nagasawa², Koichi Amano³ and Tsutomu Takeuchi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Ctr, Kawagoe, Japan, ³Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁴Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) should be divided into remission-induction phase and its maintenance phase. To date, the usefulness of the combination…
Abstract Number: 75 • 2012 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Associated with Achieving and Maintaining Low Disease Activity in Rheumatoid Arthritis
Martin J. Bergman¹, James W. Shaw², Mary Cifaldi³, Gourab De⁴, Tony He⁵, Rajeev Ayyagari⁵ and James Signorovitch⁵, ¹Taylor Hospital, Ridley Park, PA, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: Treat-to-target (T2T) guidelines for rheumatoid arthritis (RA) recognize low disease activity (LDA) as an acceptable therapeutic goal, particularly in patients with longstanding disease. The…
Abstract Number: 1684 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Major Cardiovascular Events in a Nationwide Cohort of Rheumatoid Arthritis Patients Treated with Biological Agents
Signe Abitz Winther¹, Peter Riis Hansen¹, Søren Lund Kristensen¹, Lene Dreyer², Ole Ahlehoff¹, Louise Linde³, Christian Torp-Pedersen¹ and Jesper Lindhardsen¹, ¹Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ³Internal Medicine - Rheumatology Section, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease, but in contrast to the well-established risk of myocardial infarction (MI), the…
Abstract Number: 1294 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis
Melvin A. Churchill¹, Luis F. Flores-Suarez², Daniel J. Wallace³, Kristine Phillips⁴, Richard W. Martin⁵, Mario H. Cardiel⁶, Jeffrey Kaine⁷, Edgar Bautista⁸, David H. Salinger⁹, Erin Stevens⁹, Christopher B. Russell⁹ and David A. Martin⁹, ¹Arthritis Center of Nebraska, Lincoln, NE, ²Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ⁶Research Unit, Hospital, Morelia, Mexico, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Medical Sciences, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: The cytokine IL-17A is an innate inflammatory cytokine implicated in the pathogenesis of several human autoimmune diseases including rheumatoid arthritis (RA). Brodalumab is…
Abstract Number: 487 • 2012 ACR/ARHP Annual Meeting
Functional Disability in Early Rheumatoid Arthritis – Contributions of Disease Activity and Structural Damage, and the Impact of Different Treatment Strategies
Josef S. Smolen¹, Roy Fleischmann², Paul Emery³, Ronald F. van Vollenhoven⁴, Stefan Florentinus⁵, Freddy Faccin⁶, Suchitrita S. Rathmann⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Abbott Laboratories, Abbott Park, IL, ⁸Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁹UCSD School of Medicine, La Jolla, CA
Background/Purpose: Functional impairment among patients with rheumatoid arthritis (RA) can be conceptualized as consisting of a reversible component that relates to disease activity (ACT-HAQ) and…
Abstract Number: 84 • 2012 ACR/ARHP Annual Meeting
Benefits of Treat-to-Target Guideline Compliance in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis
Martin J. Bergman¹, James W. Shaw², Mary A. Cifaldi³, Annie Guerin⁴, Pooja Chopra⁵ and James Signorovitch⁵, ¹Taylor Hospital, Ridley Park, PA, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., Montreal, QC, Canada, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: To achieve clinical remission/low disease activity in patients with rheumatoid arthritis (RA), the treat-to-target (T2T) guidelines recommend frequent disease monitoring through patient-rheumatologist interactions. The…
Abstract Number: 1636 • 2012 ACR/ARHP Annual Meeting
Commensal Gut-Derived Bacteria As Therapy for Systemic Autoimmune Disease
David Luckey¹, Eric Marietta¹, Harvinder S. Luthra², Robin Patel³, Joseph A. Murray⁴, Ashutosh Mangalam¹ and Veena Taneja¹, ¹Immunology, Mayo Clinic, Rochester, MN, ²Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ³Medicine, Mayo Clinic, Rochester, MN, ⁴Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that leads to destruction of joints. Although etiology of RA is unknown, both genetic and environmental factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].